PpProf. Peptide
Back to Peptide Library

DSIP

Sleep & RecoveryResearch-Grade

Last reviewed: May 24, 2026

Also Known As: Delta Sleep-Inducing Peptide, Emideltide, WAGGDASGE

Peptide Class: Naturally Occurring Nonapeptide — Sleep Modulator / Stress-Axis Regulator (mechanism incompletely characterized)

Regulatory Status: Not FDA-approved. FDA flagged for potential immunogenicity in compounded preparations. Not on WADA prohibited list.

What is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 from the cerebral venous blood of rabbits exhibiting deep slow-wave (delta) sleep. It is found in human brain, plasma, and breast milk. Unlike typical peptides, DSIP can cross the blood-brain barrier and is partially absorbed via the gut. Despite its name and decades of research, DSIP's role as a primary sleep-regulating compound remains uncertain — modern research describes it more accurately as a sleep-modulating substance that improves disturbed sleep without significantly affecting healthy sleepers. It also has documented anti-stress, antioxidant, and possible neuroprotective effects. New to peptide research? Start with the basics →

Reported benefits:

  • May improve slow-wave (delta) sleep depth in disturbed sleepers
  • Anti-stress: blocks corticotropin release, reduces CRF-induced corticosterone
  • Antioxidant effects in animal models
  • Possible neuroprotection in stroke models
  • Antinociceptive (pain-reducing) effects in animal research
  • No sedation in healthy individuals — modulates rather than forces sleep

Common research dose: Typical research dose: 100–200 mcg subcutaneously at bedtime. Cycle 5–7 days, then break.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes → for current options.

How does DSIP work?

DSIP's mechanism remains incompletely characterized after 50 years of research. It appears to be a sleep-modulating substance (not direct sedative) — most effective in disturbed sleepers, minimal effect on healthy sleepers. Possible targets include NMDA receptors, GABA-A and glycine receptor sites, and α1-adrenergic receptors. It also has documented anti-stress effects (blocks CRF-induced corticosterone), antioxidant activity, and hormonal modulation (LH, GH, somatostatin). The breadth of effects without a clearly identified receptor is part of why DSIP is described as 'a still unresolved riddle'.

  1. Sleep Modulation [1]. DSIP acts more as a sleep-promoting substance than a direct sedative. Its activity is greatest in subjects with disturbed sleep, with minimal effect on healthy sleepers. A dose given during the day may improve sleep on subsequent nights — suggesting downstream regulatory effects rather than acute sedation.
  2. Receptor Mechanism Unclear. DSIP's molecular targets are incompletely characterized. Its effects may involve NMDA receptors, GABA-A and glycine receptor sites, and α1-adrenergic receptors. The mechanism by which it modulates sleep architecture is not definitively established.
  3. Stress Axis Modulation [2]. DSIP decreases basal corticotropin levels and blocks ACTH release. It reduces CRF-induced corticosterone release. This anti-stress effect may be primary, with sleep effects emerging downstream of stress reduction.
  4. Antioxidant Activity [3]. DSIP has been shown to enhance the efficiency of oxidative phosphorylation in rat mitochondria and activate natural antioxidant mechanisms. A 2011 study concluded a 'strong antioxidant effect' in rat models.
  5. Hormonal and Endocrine Effects. DSIP has been observed to stimulate luteinizing hormone (LH) release, stimulate somatotrophin (GH) secretion via GHRH-like effect, and inhibit somatostatin secretion. It also normalizes blood pressure and myocardial contraction in some models.

What is DSIP used for?

DSIP's research evidence base spans disturbed sleep (most established application in early human research), stress and anxiolytic effects (Russian research), cerebral ischemia/stroke models, antinociception (pain reduction), and geroprotection (mouse study showing lifespan extension and reduced tumor incidence). Most research is from the 1970s-1990s with limited modern human clinical trials. The mechanism remains incompletely characterized.

  1. Disturbed Sleep [4]. Early human research showed DSIP improved sleep in chronic insomnia patients and normalized disturbed sleep patterns. The effect is most pronounced in patients with sleep disturbance rather than healthy sleepers.
  2. Stress and Anxiolytic Effects [2]. Russian research has explored DSIP's role in stress resistance. The peptide blocks corticotropin and reduces stress hormones in animal models, and has been associated with anxiolytic effects in rodent paradigms.
  3. Cerebral Ischemia and Stroke [5]. Multiple Russian studies show DSIP reduces ischemic damage in stroke models. A 2021 MDPI study showed intranasal DSIP improved motor function recovery in rats after focal stroke.
  4. Antinociception (Pain Reduction) [6]. Centrally administered DSIP shows antinociceptive (pain-reducing) effects in animal pain models. Mechanism unclear.
  5. Geroprotection. A long-term mouse study showed DSIP injections decreased spontaneous tumor incidence 2.6-fold, slowed age-related estrous decline, decreased chromosome aberrations 22.6%, and increased maximum lifespan 24.1%. Limited replication and species generalizability.

How long does DSIP take to work?

DSIP effects develop on multiple timescales. Acute effects on disturbed sleep may appear from the first dose, though the most consistent reports describe improved sleep over the following 1–7 days. Some research suggests DSIP given during the day produces improved sleep on subsequent nights — implying delayed/downstream effects rather than direct sedation. Long-term effects (stress resilience, antioxidant) build over weeks. Plasma half-life is short, but biological effects persist longer than pharmacokinetics would predict.

Acute effects on disturbed sleep may appear from the first dose, though the most consistent reports describe improved sleep over the following 1–7 days. Some research suggests DSIP given during the day produces improved sleep on subsequent nights — implying delayed/downstream effects rather than direct sedation. Long-term effects (stress resilience, antioxidant) build over weeks. The peptide's plasma half-life is short, but biological effects persist much longer than pharmacokinetics would predict — a recurring pattern for peptides that work through gene expression rather than direct receptor agonism.

How is DSIP dosed?

DSIP is typically administered as a subcutaneous injection at bedtime. Intravenous and intranasal routes have also been used in research. There is no standardized dosing protocol — most ranges come from limited human studies and biohacker reports. Standard research dose: 100–200 mcg subcutaneously at bedtime. Cycle 5–7 days, then break. DSIP dosing is among the least standardized of any peptide on Prof. Peptide.

  1. Standard research dose. 100–200 mcg subcutaneously at bedtime.
  2. Higher dose ranges. 250–500 mcg subcutaneously, used in some sleep protocols.
  3. Original IV human studies. 25 nmol/kg intravenously (~0.025 mcmol/kg = ~21 mcg/kg) — much lower than typical SC dosing.
  4. Cycle length. 5–7 days on, with breaks. Continuous daily long-term use is uncommon and lacks safety data.
  5. Intranasal use. 100–250 mcg before bed, similar to SC dosing.

DSIP dosing is among the least standardized of any peptide on Prof. Peptide. Original research used IV doses in nmol/kg ranges that don't translate cleanly to subcutaneous mcg dosing. Most modern protocols are derived from biohacker community reports rather than clinical trials. Start at the low end (50–100 mcg) for first-time use and titrate up only if needed.

Need to calculate your dose? Convert mg to syringe units and plan reconstitution with the dosage calculator →.

How is DSIP administered?

DSIP is administered as a subcutaneous injection at bedtime (the most common route). Intranasal alternative also used. The 30–60 minutes before sleep window is typical. Avoid combining with sedatives or alcohol — possible additive CNS depression. For SC technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection at bedtime is the most common route. Intranasal also used.
  2. Time of day. 30–60 minutes before sleep. Some protocols use daytime dosing for the next-night effect.
  3. With or without food. Either is fine — DSIP can be absorbed orally (unusual for a peptide), but injection is preferred for research dosing.
  4. Site rotation. Use a different site each injection (abdomen, thigh, upper arm).
  5. Missed dose. Skip and resume next scheduled dose. Do not double-dose.
  6. Avoid with sedatives. Avoid combining with sedatives, benzodiazepines, alcohol — possible additive CNS depression.
  7. Cycle structure. 5–7 days on, with breaks. Avoid continuous daily long-term use given limited safety data.

Timing context. DSIP's most distinctive timing feature is the “next-night effect” reported in some research — daytime dosing producing improved sleep on subsequent nights, suggesting downstream regulatory rather than acute sedative action. The plasma half-life is short, but biological effects persist far longer. The bedtime protocol is convention; the next-night protocol is an alternative used in specific research contexts.

AspectRecommendation
FrequencyOnce daily during the 5–7 day cycle
Best time of dayBedtime (30–60 min before sleep) or daytime for next-night effect
FoodNo fasting required
Route choiceSubcutaneous most common; intranasal alternative; oral absorbed (unusual for peptide)
Half-lifeShort plasma half-life; biological effects persist far longer
Steady-statePer-dose effect on sleep; cumulative anti-stress effects build over days-weeks

Reconstitution math. Choose your bacteriostatic water volume based on dose precision. DSIP research vials are typically 5 mg. Because doses are small (50–200 mcg), 2 mL reconstitution is common — it gives clean whole-number units across the typical dose range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.

BAC waterConcentration50 mcg dose100 mcg dose200 mcg dose300 mcg dose
1 mL5 mg/mL1 unit2 units4 units6 units
2 mL2.5 mg/mL2 units4 units8 units12 units
3 mL1.67 mg/mL3 units6 units12 units18 units

Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of DSIP at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does DSIP stack well with?

DSIP's safer pairings are non-peptide supplements (magnesium glycinate, L-Theanine — additive sleep support). Selank's anxiolytic effect may complement DSIP's stress-reduction. BPC-157 is compatible without direct interaction. The important non-stacking is sedatives, benzodiazepines, and alcohol — additive CNS depression risk.

  1. Magnesium glycinate. Additive sleep support; common safe combination.
  2. L-Theanine. Additive calming effect; safe combination.
  3. BPC-157. BPC-157 — different mechanism (healing/gut). No direct interaction.
  4. Selank. Selank — anxiolytic effect may complement DSIP's stress-reduction; no published interaction data.
  5. Avoid: sedatives, benzodiazepines, alcohol. Possible additive CNS depression risk.

What are the side effects of DSIP?

DSIP has the weakest safety database of any peptide on Prof. Peptide. The FDA has explicitly flagged DSIP for potential immunogenicity in compounded preparations — meaning the body may mount a potentially serious immune response. Most published safety data comes from short-term animal studies and limited human research from the 1980s–1990s. Long-term effects are unknown. The absence of harm signals in limited research is NOT the same as proven long-term safety.

Common (most users)

  1. Daytime drowsiness. If dose is too high or mistimed.
  2. Mild headache or dizziness.
  3. Mild gastrointestinal discomfort, nausea. Occasional.

Less common (moderate)

  1. Hormonal fluctuations. DSIP affects LH, GH, somatostatin.
  2. Mild fluid retention.
  3. Mild fatigue or grogginess.

Serious (rare)

  1. Potential immunogenicity. FDA has flagged DSIP for risk of immune-mediated adverse reactions in compounded preparations.
  2. Long-term safety unknown. Most research is short-term animal studies.
  3. No published cases of severe adverse events. Though clinical experience is very limited.

DSIP has the weakest safety database of any peptide on Prof. Peptide. The FDA has explicitly flagged DSIP for potential immunogenicity in compounded preparations — meaning the body may mount an immune response that is potentially serious. Most published safety data comes from short-term animal studies and limited human research from the 1980s–1990s. Long-term effects are unknown. The 2001 European Journal of Anaesthesiology editorial described DSIP as “incredibly safe” based on the lack of acute toxicity in animal studies, but the absence of harm signals in limited research is not the same as proven long-term safety.

Does DSIP interact with other drugs?

DSIP's relevant interactions are with sedatives and benzodiazepines (possible additive CNS depression — combine with caution), alcohol (limited data, avoid combination), and hormonal medications (DSIP affects LH, GH, somatostatin — theoretical interaction with hormone replacement or fertility treatments). No major drug-drug interactions formally documented (largely because DSIP has limited modern clinical study).

  1. Sedatives and benzodiazepines. Possible additive CNS depression; combine with caution.
  2. Alcohol. Limited data; avoid combination given DSIP's CNS effects.
  3. Hormonal medications. DSIP affects LH, GH, somatostatin; theoretical interaction with hormone replacement or fertility treatments.
  4. No major drug-drug interactions formally documented (largely because DSIP has limited modern clinical study).

How should DSIP be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
  2. Reconstituted solution: Store at 2–8°C; use within 14–28 days.
  3. Reconstitute with bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. Never freeze reconstituted solution.
  5. Protect from light. Store in original carton.
  6. Discard if cloudy, discolored, or contains particles.

What are the limitations of DSIP research?

DSIP has one of the weakest evidence bases of any peptide on Prof. Peptide. NOT FDA-approved. FDA has explicitly flagged DSIP-containing compounded drugs for potential immunogenicity risk. Most research is from the 1970s–1990s with limited modern human clinical trials. Mechanism remains incompletely characterized after 50 years. Conflicting evidence on sleep effects — some studies failed to replicate original findings. Described as 'a fascinating but unfinished chapter in peptide research'.

DSIP has one of the weakest evidence bases of any peptide on Prof. Peptide. It is NOT FDA-approved for any human use. The FDA has explicitly flagged DSIP-containing compounded drugs for potential immunogenicity risk, meaning the body may perceive DSIP as a threat and mount a potentially serious immune response.

Most published research on DSIP comes from the 1970s–1990s, with limited modern human clinical trials. The mechanism of action remains incompletely characterized after 50 years of research. Some studies failed to replicate the original sleep-promoting findings. Modern reviewers describe DSIP as “a fascinating but unfinished chapter in peptide research” rather than a proven sleep therapy.

Conflicting evidence exists on DSIP's involvement in sleep regulation — some studies link it to slow-wave sleep promotion and REM suppression, others show no consistent sleep effects. The original “delta sleep-inducing” name reflects the discovery context, not validated clinical action.

Research-grade DSIP material is sold for laboratory use only. Purity and potency vary by vendor — and given the FDA's immunogenicity flag, third-party testing is especially important for any DSIP product.

The World Anti-Doping Agency does not currently include DSIP on the prohibited list, but the peptide's effects on GH and LH could theoretically have sport-related implications.

Where to source DSIP

DSIP is not FDA-approved and is sold by specialty research peptide vendors. Quality varies and the FDA has flagged immunogenicity concerns — third-party testing is especially important. The vendors highlighted below have been vetted — including nasal and pre-blended (Asleep) format options.

Behemoth Labz10% off

Nasal format

Click to copy code

Shop Behemoth Labz →
PureRawz10% off

Available in Youth Nasal Spray + Asleep blends

Click to copy code

Shop PureRawz →
Ascension Peptides50% off
Best Deal

Click to copy code

Shop Ascension Peptides →

See all 17 verified vendors →

DSIP FAQ

Does DSIP actually induce sleep?

The original name reflects the 1977 discovery context — DSIP was isolated from rabbits in deep delta-wave sleep. Modern research describes DSIP more accurately as a sleep-modulating substance that improves disturbed sleep with minimal effect on healthy sleepers. It is NOT a direct sedative like a benzodiazepine. Some research even shows DSIP given during the day produces improved sleep on the next night — suggesting downstream regulatory effects, not acute sedation.

Is DSIP safe?

Long-term safety is not established. Available animal studies show low acute toxicity, but the FDA has explicitly flagged DSIP for potential immunogenicity — meaning the body may mount an immune response. Most modern human clinical experience is anecdotal and limited. DSIP has the weakest safety database of any peptide on Prof. Peptide.

How does DSIP differ from melatonin?

Mechanism completely different. Melatonin regulates sleep timing through circadian receptors. DSIP appears to affect sleep depth and recovery quality, with possible anti-stress and hormonal effects. Melatonin has decades of human safety data; DSIP has very limited modern human research. Melatonin is generally a safer first choice for sleep difficulty.

Why does DSIP appear in breast milk?

DSIP-like substances are present in human breast milk at higher concentrations than in plasma. Some researchers have hypothesized this contributes to post-feeding sleep tendencies in newborns, though this remains unproven.

What's the right dose?

There is no standardized clinical dose. Original IV human studies used 25 nmol/kg (~21 mcg/kg). Modern subcutaneous protocols typically use 100–200 mcg per dose, but this is derived from biohacker community reports rather than clinical trials. Start low (50–100 mcg) and titrate up only if needed.

Should I take DSIP daily?

Continuous daily long-term use lacks safety data. Most protocols use 5–7 days on with breaks. Given the FDA's immunogenicity flag and limited human clinical experience, conservative cycling is the prudent approach.

How does DSIP compare to other sleep peptides?

DSIP is the only widely-discussed 'sleep peptide' with substantial historical research. Other sleep-related peptides (orexin antagonists, melatonin analogs) work through different mechanisms and have stronger clinical evidence. For severe sleep disturbance, DSIP should NOT be a first-line option — established treatments with FDA approval and known safety profiles are safer choices.

Where can I buy DSIP?

DSIP is not FDA-approved and is sold by specialty research peptide vendors. Quality varies and the FDA has flagged immunogenicity concerns — third-party testing is especially important. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes →.

References

  1. Pollard BJ, Pomfrett CJ. Delta sleep-inducing peptide. Eur J Anaesthesiol. 2001;18(7):419-22. https://pubmed.ncbi.nlm.nih.gov/11437868/
  2. Graf MV, Kastin AJ, Coy DH, Fischman AJ. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985;41(5):353-6. https://pubmed.ncbi.nlm.nih.gov/2999626/
  3. Wikipedia. Delta-sleep-inducing peptide. https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
  4. Schneider-Helmert D. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-5. https://pubmed.ncbi.nlm.nih.gov/6895513/
  5. Khvatova EM, Belousova ID, Sazanova EI, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173. https://www.mdpi.com/1420-3049/26/17/5173
  6. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. https://pubmed.ncbi.nlm.nih.gov/6437793/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

PNAS · 1977Open Access
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide →

Schoenenberger GA, Monnier M.

The foundational paper that isolated and characterized DSIP from rabbit cerebral venous blood. Researchers demonstrated that the nonapeptide induced increases in delta-wave EEG activity when administered to rabbits, establishing both the compound and its name.

Neuroscience and Biobehavioral Reviews · 1984Abstract available
Delta-sleep-inducing peptide (DSIP): a review →

Graf MV, Kastin AJ.

A comprehensive review synthesizing the first decade of DSIP research. The paper covers DSIP's effects on sleep, hormone release, stress response, and thermoregulation across multiple species.

Journal of Neurochemistry · 2006Open Access
Delta sleep-inducing peptide (DSIP): a still unresolved riddle →

Kovalzon VM, Strekalova TV.

A critical review examining why DSIP remains incompletely understood despite decades of research. The authors discuss the lack of a definitively identified receptor, the inconsistency of sleep findings, and the broad range of reported effects.

Brain Research · 1987Abstract available
The effects of DSIP on wakefulness and sleep patterns in the cat →

Susić V, Masirevic G, Totic S.

A classic experimental study examining DSIP's effects on sleep architecture in cats using EEG recording. The researchers documented significant increases in slow-wave sleep and reduced sleep latency after DSIP administration.

Peptides · 1986Abstract available
Delta-sleep-inducing peptide: an update →

Graf MV, Kastin AJ.

A follow-up review to the 1984 paper, summarizing the second wave of DSIP research and proposing refinements to the understanding of its mechanism.

Sleep & RecoveryNeuropeptideStress ModulationResearch-Grade

Related Peptides

SelankSemaxEpitalonBPC-157

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

We may earn commissions from peptide vendor affiliate links.

Have a question about DSIP? Send us an email →

For educational and research purposes only. Not medical advice. Not for human use.